Overwatch Research

Overwatch Research was a Belfast, Northern Ireland-based software company that built a configurable, end-to-end study management and execution system for preclinical in vivo research. The platform covered the full preclinical workflow: study design, animal randomization, task tracking and scheduling, data collection (including hardware integrations), data analysis, visualization and reporting, with experimental data held in a central location so study results could be visualized immediately rather than tracked in spreadsheets and email threads.

The company positioned the product against the preclinical "reproducibility crisis" — the widely documented failure of preclinical experiments to replicate, which sources cite as costing roughly $28 billion per year in the U.S., with other estimates of the economic cost of irreproducible biomedical research at $10-50 billion annually. Overwatch's approach was to remove sources of bias and error before a study starts, via a "study creation engine" in which the scientist specifies the model or study type and the rest of the study structure, including suggested statistical tests and data formats, follows from that choice. Management emphasized consumer-grade user experience as a differentiator in life-science software, citing a one-hour product demo and about five minutes to onboard a new user.

Following the February 2022 acquisition by Benchling, the technology became Benchling In Vivo, offered as part of Benchling's R&D Cloud. As marketed today it provides reusable study templates with multi-step design approval, result-level data capture per animal linked to treatment, group and sample data, multi-parameter randomization algorithms, task management, real-time analytics from a centralized study database, and configurable animal welfare alert thresholds for body weight loss or experimental endpoints. It supports efficacy, tolerability, survival, and behavior and weight monitoring studies with multiple arms, groups and timepoints, maintains audit trails and electronic signatures, allows multi-site and CRO collaboration with role-based permissions, and is built on the same platform as Benchling Bioresearch so in vivo data is traceable to in vitro experiments; Benchling AI can query the combined dataset and assist with study report preparation.

Founding story

CEO and co-founder Chris Armstrong conceived the product during his career in prostate cancer drug development, where study management still depended on spreadsheets and email trails. He and co-founders Paul and Graham Wilsdon founded the company in 2017 after becoming frustrated with the study and data management methods used in preclinical drug development, and validated the problem through interviews with more than 250 biotech and pharma companies.

Business model

Software vendor selling licensed access to its study management platform to biopharmaceutical companies, CROs and academic research organizations; deals reported included multi-year licenses, such as a five-year license with a top-10 pharmaceutical company. Post-acquisition the product is sold as a module of Benchling's R&D Cloud.

Software licensing, including multi-year license agreements with pharmaceutical customers.

Traction

By October 2021 the company had closed 20 deals with biotech companies in the United States and 15 in Europe, including one five-year license with a top-10 pharmaceutical company, with three further major pharmaceutical companies in discussion; 60% of the existing customer base was in the U.S. Named customers and partners include Lyell Immunopharma and The Institute for Cancer Research, London. The Benchling platform on which the product now sits states it powers over 1,300 biotechnology companies.

Latest developments

Benchling completed the acquisition on 24 February 2022 for an undisclosed sum and integrated Overwatch's capabilities into its R&D Cloud. The offering is now marketed as Benchling In Vivo, with added Benchling AI capabilities for cross-study querying and automated preparation of preclinical study reports and for structuring CRO-delivered data.